Clinical Trial Update: A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated whether nemolizumab affects cytochrome P450–mediated drug metabolism in adults with moderate-to-severe atopic dermatitis; results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-12-05